Novo Nordisk, the manufacturer of Ozempic and Wegovy, announced a rebrand to Novo on Monday. The company will maintain its legal name while adopting the shortened identity and an updated bull logo for daily communications and packaging. This strategic shift aims to increase brand relevance in a competitive, consumer-driven market.
The announcement precedes the company’s Capital Markets Day on September 21. CEO Mike Doustdar stated the move seeks to reinvent the company and connect with a growing demographic of weight loss users.
The pharmaceutical giant also introduced a new corporate culture called The Novo Way. This framework prioritizes customer obsession, competitiveness, clarity, and care.